Literature DB >> 14965380

Transduction of long-term and mobilized peripheral blood-derived NOD/SCID repopulating cells by foamy virus vectors.

Neil C Josephson1, Grant Trobridge, David W Russell.   

Abstract

Foamy virus (FV) vectors are a promising gene delivery system for use in hematopoietic stem cell gene therapy. Previous FV vector marking studies in the NOD/SCID xenotransplantation model used umbilical cord blood (UCB)-derived SCID repopulating cells (SRCs) that were assayed 5-10 weeks posttransplantation. We now report efficient FV vector transduction (>65%) of UCB-derived primitive, long-term SRCs engrafted for 18 weeks. In addition, we evaluated gene transfer into mobilized peripheral blood (MPB)-derived SRCs by improved, deleted FV vectors containing minimal cis-acting sequences and packaged by split helper constructs that would be appropriate for use in clinical trials. When used at a multiplicity of infection of 1 in a 10-hr transduction protocol, these improved vectors transduced 34% of engrafted MPB-derived SRCs.

Entities:  

Mesh:

Year:  2004        PMID: 14965380     DOI: 10.1089/10430340460732481

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  25 in total

1.  Nonintegrating foamy virus vectors.

Authors:  David R Deyle; Yi Li; Erik M Olson; David W Russell
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Foamy virus vector integration sites in normal human cells.

Authors:  Grant D Trobridge; Daniel G Miller; Michael A Jacobs; James M Allen; Hans-Peter Kiem; Rajinder Kaul; David W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-20       Impact factor: 11.205

3.  Characterization of the prototype foamy virus envelope glycoprotein receptor-binding domain.

Authors:  Anja Duda; Daniel Lüftenegger; Thomas Pietschmann; Dirk Lindemann
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

4.  Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome.

Authors:  Toru Uchiyama; Marsilio Adriani; G Jayashree Jagadeesh; Adam Paine; Fabio Candotti
Journal:  Mol Ther       Date:  2012-01-03       Impact factor: 11.454

5.  Tracking of specific integrant clones in dogs treated with foamy virus vectors.

Authors:  Ken Ohmine; Yi Li; Thomas R Bauer; Dennis D Hickstein; David W Russell
Journal:  Hum Gene Ther       Date:  2010-12-19       Impact factor: 5.695

6.  Foamy-virus-mediated gene transfer to canine repopulating cells.

Authors:  Hans-Peter Kiem; James Allen; Grant Trobridge; Erik Olson; Kirsten Keyser; Laura Peterson; David W Russell
Journal:  Blood       Date:  2006-09-12       Impact factor: 22.113

7.  Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.

Authors:  Michael Aaron Goodman; Paritha Arumugam; Devin Marie Pillis; Anastacia Loberg; Mohammed Nasimuzzaman; Danielle Lynn; Johannes Christiaan Maria van der Loo; Phillip Joseph Dexheimer; Mehdi Keddache; Thomas Roy Bauer; Dennis Durand Hickstein; David William Russell; Punam Malik
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

8.  Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy.

Authors:  Olivier Humbert; Frieda Chan; Yogendra S Rajawat; Troy R Torgerson; Christopher R Burtner; Nicholas W Hubbard; Daniel Humphrys; Zachary K Norgaard; Patricia O'Donnell; Jennifer E Adair; Grant D Trobridge; Andrew M Scharenberg; Peter J Felsburg; David J Rawlings; Hans-Peter Kiem
Journal:  Blood Adv       Date:  2018-05-08

9.  In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector.

Authors:  Shanbao Cai; Aaron Ernstberger; Haiyan Wang; Barbara J Bailey; Jennifer R Hartwell; Anthony L Sinn; Olaf Eckermann; Yvonne Linka; W Scott Goebel; Helmut Hanenberg; Karen E Pollok
Journal:  Exp Hematol       Date:  2008-03       Impact factor: 3.084

10.  Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.

Authors:  Rui-Jun Su; Angela Epp; Yvette Latchman; Doug Bolgiano; Steven W Pipe; Neil C Josephson
Journal:  Mol Ther       Date:  2009-09-15       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.